Focus: Tenaya Therapeutics is a public biotech company focused on cardiovascular and metabolic disease therapeutics, operating as a clinical-stage developer with no approved products on the market.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Only consider if you have high risk tolerance and believe in the company's capital raise capability; career stability is materially at risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tenaya Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tenaya Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by Analysts MarketBeat
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) ChartMill
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 - The Manila Times
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 The Manila Times
Tenaya to show 1-year heart gene therapy data in late-breaking talk - Stock Titan
Tenaya to show 1-year heart gene therapy data in late-breaking talk Stock Titan
Tenaya Therapeutics Announces Late-Breaking Oral - GlobeNewswire
Tenaya Therapeutics Announces Late-Breaking Oral GlobeNewswire
TNYA Tenaya Therapeutics Inc. shares gain over 4 percent after Q4 2025 earnings narrowly top analyst consensus estimates. - Crowd Consensus Signals - UBND thành phố Hải Phòng
TNYA Tenaya Therapeutics Inc. shares gain over 4 percent after Q4 2025 earnings narrowly top analyst consensus estimates. - Crowd Consensus Signals UBND thành phố Hải Phòng
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo